Prior work suggests that chemogenetic stimulation of D2-MSNs abolishes the therapeutic response to levodopa in parkinsonian mice.46 To investigate how chemogenetic inhibition of D2-MSNs impacts dyskinesia expression, we delivered an IP injection of CNO followed by an IP injection of low-dose levodopa or saline. The gene discussed is BLOC1S4; the disease is drug-induced dyskinesia.